In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report). The company’s shares closed today at $8.02.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Roy is an analyst with an average return of -25.6% and a 18.62% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Nuvation Bio, and Enliven Therapeutics.
Elicio Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
The company has a one-year high of $9.99 and a one-year low of $3.34. Currently, Elicio Therapeutics has an average volume of 45.78K.
Read More on ELTX: